Sandra Swain, MD on Phase 3 CLEOPATRA Study @SandraSwainMD @LombardiCancer

Sandra Swain, MD on Phase 3 CLEOPATRA Study @SandraSwainMD @LombardiCancer

User Photo

8 months
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer.


CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA's final-of-study review.

Read here:

Up Next Autoplay